TENSIVE CONTROLS, INC.

Biotech · Private

A melanocortin antagonist peptide therapeutic (TCMCB07) with extended half-life to treat cachexia-anorexia syndrome

Grants
$2.6M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
10
4 granted · 6 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Agriculture · Development Of Anti-microbial Peptide Therapeutics$99,478
Federal grantDepartment of Health and Human Services · Phase II · Development of a Cancer Cachexia Therapeutic$204,519
Federal grantDepartment of Health and Human Services · Phase II · Development of a Cancer Cachexia Therapeutic$898,017
Federal grantDepartment of Health and Human Services · Phase II · Development of a Cancer Cachexia Therapeutic$1,415,204
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2239Forecast Bio, Inc.—$2.4M
2240Monocacy Therapeutics Inc.—$389K
2241POWERHOUSE PROTEOMIC SYSTEMS, LLC——
2242TENSIVE CONTROLS, INC.——
2243Acelyrin——
2244Cour Pharmaceutical——
2245AVEXEGEN THERAPEUTICS INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 4 granted of 10

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.